GILD
Gilead Sciences, Inc.
$148.95
Market Cap$115.0B
P/E Ratio14.0
Dividend Yield3.20%
Beta0.39
Employees17,600
Price Chart
Loading chart...
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
AI Research Brief
AI GeneratedInvestment Thesis
Gilead Sciences, Inc. (GILD) is a compelling BUY at the current price of $148.95, primarily due to its strong position in high-demand therapeutic areas, particularly HIV and oncology. The market is underestimating Gilead's growth potential driven by its expanding product pipeline and strategic collaborations, which position the company favorably against competitors. Given its historical resilience and the ongoing need for innovative treatments, the current valuation does not fully reflect the fundamental strength and future cash flow potential of the business.
Competitive Moat
characterized primarily by intangible assets, including a strong portfolio of patents and regulatory approvals, which protect its innovative therapies from generic competition. The company's established brand in the HIV market and its reputation for quality enhance its competitive position. While competition from emerging biotech firms poses a threat, particularly in the oncology space, Gilead's scale and deep R&D capabilities provide a durable advantage over the next 5-10 years, especially as it continues to expand its pipeline.
Growth Engine
Future revenue growth for Gilead is poised to come from both organic growth through its existing product lines and promising new therapies currently in development. The total addressable market (TAM) for HIV and liver diseases remains substantial, estimated at over $20 billion collectively, with Gilead holding a significant market share. Additionally, its investments in oncology and cell therapy present opportunities for expansion into high-growth markets. The company is gaining market share in these sectors, particularly with its CAR-T therapies like Yescarta, which are seeing increasing adoption.
Capital Allocation
strategy appears prudent, with a balanced approach to reinvestment in R&D and strategic acquisitions aimed at bolstering its pipeline without excessive dilution. While Gilead has historically focused on share buybacks, recent efforts have shifted towards funding clinical trials and expanding its portfolio, which aligns with long-term value creation. There are no immediate red flags regarding capital management, as the company maintains a healthy balance sheet and a disciplined approach to growth.
Valuation Check
At a price of $148.95, Gilead's stock is fairly priced relative to its earnings power and growth outlook, despite the current P/E ratio being N/A due to ongoing investments in R&D. Historically, Gilead has traded at an average P/E in the mid-teens; thus, the current valuation reflects a cautious market outlook. However, the implicit growth expectations are conservative considering the potential upside from new product launches and expanding markets. The market may be underpricing Gilead's ability to monetize its innovative therapies effectively.
Key Risks
- Regulatory Risks: Changes in healthcare regulations or adverse outcomes from clinical trials could lead to significant delays or denials in product approvals, impacting revenue projections.
- Competitive Disruption: The rapid pace of innovation in biopharmaceuticals could lead to the emergence of better therapies by competitors, particularly in oncology and HIV, potentially eroding Gilead's market share.
- Customer Concentration: A significant portion of Gilead's revenue is derived from a few key products; any decline in demand for these therapies could severely impact overall performance.
Catalyst Watchlist
- Upcoming Quarterly Earnings: Monitoring the earnings release for Q1 2026, which may provide insights into the performance of its core products and pipeline advancements.
- Product Launches: The anticipated launch of new therapies in the oncology segment in 2026 could act as a significant growth driver and positively influence stock performance.
- Regulatory Decisions: Key approvals from the FDA for late-stage pipeline candidates would serve as critical catalysts for growth and could bolster investor confidence.
Position Sizing Signal
Gilead represents a strong core holding for long-term investors seeking exposure to the biopharmaceutical sector. Given the current market dynamics and growth potential, a full position is warranted for those with a high conviction in Gilead's future. A price pullback below $140 or significant negative news related to pipeline developments would prompt a reevaluation of the thesis. Conversely, any positive regulatory outcomes or strong quarterly performances could further solidify Gilead's growth narrative and support additional investment.
This analysis is AI-generated using publicly available market data and is for informational purposes only. It does not constitute investment advice. Always conduct your own research before making investment decisions.
Research generated 2026-03-01
Related Stocks
Ready to Invest in GILD?
Robinhood
Commission-free trades with no account minimums. Get started in minutes.
Trade on Robinhood →
We may earn a commission if you open an account through our links, at no extra cost to you.
Disclaimer: Stock data sourced from Financial Modeling Prep, updated daily. Prices may be delayed. Interactive charts powered by TradingView. This page is for informational and educational purposes only and does not constitute investment advice. We are not licensed financial advisors. Please consult a qualified professional before making investment decisions.
Privacy Policy · Terms
Privacy Policy · Terms